Live
FierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection pointFierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regressionPharmaVoice3 potential takeover targets in obesityFierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-makingFierceBiotechBiopharma IPOs: Timing, capital and staying flexibleRoche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical TechnologyEndpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealEndpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealEndpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B
BioWorld 31 déc. 2025

Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing

Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing

Original
Contenu indisponible. Consultez la source originale.